Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 97702695 | 9770269 | 5 | F | 201312 | 20160809 | 20131218 | 20160810 | EXP | US-FRI-1000052307 | FOREST | 64.29 | YR | F | Y | 68.95000 | KG | 20160810 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 97702695 | 9770269 | 1 | PS | SAVELLA | MILNACIPRAN HYDROCHLORIDE | 1 | Oral | 12.5 MG | Y | 364572 | 22256 | 12.5 | MG | TABLET | QD | ||||
| 97702695 | 9770269 | 2 | SS | SAVELLA | MILNACIPRAN HYDROCHLORIDE | 1 | Oral | 25 MG | Y | 364572 | 22256 | 12.5 | MG | TABLET | BID | ||||
| 97702695 | 9770269 | 3 | SS | SAVELLA | MILNACIPRAN HYDROCHLORIDE | 1 | Oral | 50 MG | Y | 364572 | 0 | 25 | MG | TABLET | BID | ||||
| 97702695 | 9770269 | 4 | SS | SAVELLA | MILNACIPRAN HYDROCHLORIDE | 1 | Oral | 100 MG | Y | 364572 | 0 | 50 | MG | TABLET | BID | ||||
| 97702695 | 9770269 | 5 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Oral | 2000 MG, WITH MEALS | 0 | 1000 | MG | TABLET | BID | ||||||
| 97702695 | 9770269 | 6 | C | VICTOZA | LIRAGLUTIDE | 1 | 2-PAK 0.6 MG/0.1ML (18MG/3ML), 1.8 MG INTO SKIN DAILY | 0 | 1.8 | MG | |||||||||
| 97702695 | 9770269 | 7 | C | LOSARTAN. | LOSARTAN | 1 | Oral | 50 MG | 0 | 50 | MG | TABLET | QD | ||||||
| 97702695 | 9770269 | 8 | C | HYDROCHLOROTHIAZIDE. | HYDROCHLOROTHIAZIDE | 1 | Oral | 12.5 MG | 0 | 12.5 | MG | CAPSULE | QD | ||||||
| 97702695 | 9770269 | 9 | C | NORVASC | AMLODIPINE BESYLATE | 1 | Oral | 5 MG | 0 | 5 | MG | TABLET | QD | ||||||
| 97702695 | 9770269 | 10 | C | PRAVASTATIN. | PRAVASTATIN | 1 | Oral | 40 MG | 0 | 40 | MG | TABLET | QD | ||||||
| 97702695 | 9770269 | 11 | C | PRISTIQ EXTENDED-RELEASE | DESVENLAFAXINE SUCCINATE | 1 | Oral | 50 MG | 0 | 50 | MG | TABLET | QD | ||||||
| 97702695 | 9770269 | 12 | C | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | 50 MG | 0 | 50 | MG | TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 97702695 | 9770269 | 1 | Fibromyalgia |
| 97702695 | 9770269 | 5 | Type 2 diabetes mellitus |
| 97702695 | 9770269 | 6 | Diabetes mellitus |
| 97702695 | 9770269 | 7 | Hypertension |
| 97702695 | 9770269 | 8 | Hypertension |
| 97702695 | 9770269 | 9 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 97702695 | 9770269 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 97702695 | 9770269 | Acute kidney injury | |
| 97702695 | 9770269 | Alopecia | |
| 97702695 | 9770269 | Bandaemia | |
| 97702695 | 9770269 | Cardiac murmur | |
| 97702695 | 9770269 | Constipation | |
| 97702695 | 9770269 | Drug reaction with eosinophilia and systemic symptoms | |
| 97702695 | 9770269 | Dysphagia | |
| 97702695 | 9770269 | Dyspnoea | |
| 97702695 | 9770269 | Haemorrhoids | |
| 97702695 | 9770269 | Hypersensitivity | |
| 97702695 | 9770269 | Hypokalaemia | |
| 97702695 | 9770269 | Hypophagia | |
| 97702695 | 9770269 | Irritability | |
| 97702695 | 9770269 | Odynophagia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 97702695 | 9770269 | 1 | 20131129 | 20131129 | 0 | |
| 97702695 | 9770269 | 2 | 20131130 | 20131201 | 0 | |
| 97702695 | 9770269 | 3 | 20131202 | 20131205 | 0 | |
| 97702695 | 9770269 | 4 | 20131206 | 20131208 | 0 |